vs
Side-by-side financial comparison of CuriosityStream Inc. (CURI) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $19.2M, roughly 1.5× CuriosityStream Inc.). CuriosityStream Inc. runs the higher net margin — -19.7% vs -147.1%, a 127.4% gap on every dollar of revenue. On growth, CuriosityStream Inc. posted the faster year-over-year revenue change (35.8% vs -67.6%).
Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
CURI vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.2M | $28.1M |
| Net Profit | $-3.8M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | -17.6% | -147.6% |
| Net Margin | -19.7% | -147.1% |
| Revenue YoY | 35.8% | -67.6% |
| Net Profit YoY | -34.6% | -182.8% |
| EPS (diluted) | $-0.07 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $19.2M | $28.1M | ||
| Q3 25 | $18.4M | $32.5M | ||
| Q2 25 | $19.0M | $15.7M | ||
| Q1 25 | $15.1M | $8.0M | ||
| Q4 24 | $14.1M | $86.6M | ||
| Q3 24 | $12.6M | $2.1M | ||
| Q2 24 | $12.4M | $500.0K | ||
| Q1 24 | $12.0M | $0 |
| Q4 25 | $-3.8M | $-41.3M | ||
| Q3 25 | $-3.7M | $-51.2M | ||
| Q2 25 | $784.0K | $-44.9M | ||
| Q1 25 | $319.0K | $-33.9M | ||
| Q4 24 | $-2.8M | $49.9M | ||
| Q3 24 | $-3.1M | $-19.1M | ||
| Q2 24 | $-2.0M | $-12.5M | ||
| Q1 24 | $-5.0M | $-10.3M |
| Q4 25 | -17.6% | -147.6% | ||
| Q3 25 | -24.5% | -163.7% | ||
| Q2 25 | 2.5% | -302.9% | ||
| Q1 25 | 0.5% | -466.3% | ||
| Q4 24 | -27.4% | 54.5% | ||
| Q3 24 | -25.8% | -1051.6% | ||
| Q2 24 | -20.6% | -3068.0% | ||
| Q1 24 | -30.4% | — |
| Q4 25 | -19.7% | -147.1% | ||
| Q3 25 | -20.4% | -157.4% | ||
| Q2 25 | 4.1% | -285.6% | ||
| Q1 25 | 2.1% | -425.7% | ||
| Q4 24 | -19.9% | 57.7% | ||
| Q3 24 | -24.3% | -925.0% | ||
| Q2 24 | -16.4% | -2503.2% | ||
| Q1 24 | -42.0% | — |
| Q4 25 | $-0.07 | $-0.41 | ||
| Q3 25 | $-0.06 | $-0.52 | ||
| Q2 25 | $0.01 | $-0.46 | ||
| Q1 25 | $0.01 | $-0.35 | ||
| Q4 24 | $-0.05 | $0.52 | ||
| Q3 24 | $-0.06 | $-0.20 | ||
| Q2 24 | $-0.04 | $-0.13 | ||
| Q1 24 | $-0.09 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.3M | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $41.5M | $114.3M |
| Total Assets | $75.7M | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.3M | $245.0M | ||
| Q3 25 | $27.8M | $288.2M | ||
| Q2 25 | $28.1M | $240.1M | ||
| Q1 25 | $33.4M | $275.7M | ||
| Q4 24 | $32.1M | $314.0M | ||
| Q3 24 | $33.2M | $204.6M | ||
| Q2 24 | $39.5M | $218.7M | ||
| Q1 24 | $38.8M | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $41.5M | $114.3M | ||
| Q3 25 | $47.2M | $147.7M | ||
| Q2 25 | $49.8M | $192.3M | ||
| Q1 25 | $58.1M | $229.0M | ||
| Q4 24 | $57.8M | $256.8M | ||
| Q3 24 | $62.2M | $201.0M | ||
| Q2 24 | $64.8M | $215.2M | ||
| Q1 24 | $67.0M | $223.9M |
| Q4 25 | $75.7M | $327.7M | ||
| Q3 25 | $74.7M | $372.8M | ||
| Q2 25 | $78.7M | $313.5M | ||
| Q1 25 | $85.3M | $327.3M | ||
| Q4 24 | $86.2M | $351.2M | ||
| Q3 24 | $87.6M | $217.6M | ||
| Q2 24 | $90.9M | $222.0M | ||
| Q1 24 | $94.6M | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.0M | $-43.5M |
| Free Cash FlowOCF − Capex | $3.9M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.0M | $-43.5M | ||
| Q3 25 | $4.4M | $-47.0M | ||
| Q2 25 | $2.8M | $-39.6M | ||
| Q1 25 | $1.9M | $-40.7M | ||
| Q4 24 | $3.0M | $42.0M | ||
| Q3 24 | $2.3M | $-14.5M | ||
| Q2 24 | $2.2M | $-7.3M | ||
| Q1 24 | $666.0K | $-6.7M |
| Q4 25 | $3.9M | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | $1.8M | $-40.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | 20.5% | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | — | -252.2% | ||
| Q1 25 | 12.2% | -512.1% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% | ||
| Q1 24 | — | — |
| Q4 25 | 0.1% | 0.0% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.5% | 1.1% | ||
| Q4 24 | 0.0% | 0.3% | ||
| Q3 24 | 0.0% | 6.8% | ||
| Q2 24 | 0.0% | 7.6% | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.56× | — | ||
| Q1 25 | 6.03× | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CURI
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
